- PharmaCielo (PCLO) has made an initial shipment of CBD Isolate to a specialty biotechnology company based in South Africa
- The customer specializes in offering GMP certified private label cannabinoid pharmaceutical products to customers in advanced medical cannabis markets globally, including the U.K. and Australia
- The Toronto-based company has shipped CBD Isolate to facilitate pre-commercial testing before it is included into the customer’s private label products
- PharmaCielo Ltd. (PCLO) opened trading at $0.175
PharmaCielo (PCLO) has made an initial shipment of CBD Isolate to a specialty biotechnology company based in South Africa.
The customer specializes in offering GMP certified private label cannabinoid pharmaceutical products to customers in advanced medical cannabis markets globally, including the U.K. and Australia.
The Toronto-based company has shipped CBD Isolate to facilitate pre-commercial testing before it is included into the customer’s private label products.
PharmaCielo’s CEO, Bill Petron said this is the company’s first shipment to South Africa, their second market on the African continent.
“This customer has significant operations in South Africa and Europe, as well as multiple distribution hubs globally. We expect they will be an important growth partner, bringing an established supply chain that can rapidly scale the presence of our APIs across multiple global markets. PharmaCielo is steadily building its reputation as a premier global provider for high quality cannabinoid APIs at scale. With products at various stages of testing and sales in 11 countries, we expect the next twelve months to be a period of significant growth for the company as our team continues to deliver against its robust pipeline of opportunities.”
PharmaCielo is a pharma company supplying pharmaceutical-grade medicinal cannabis products. The company’s principal and wholly owned subsidiary is PharmaCielo Colombia Holdings S.A.S. Its headquarters is at its cultivation and processing center located in Rionegro, Colombia.
PharmaCielo Ltd. (PCLO) opened trading at $0.175.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
